Literature DB >> 10960663

Immune-mediated disease pathogenesis in respiratory syncytial virus infection.

B S Graham1, T R Johnson, R S Peebles.   

Abstract

Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in persons at both extremes of age. Wheezing is a cardinal sign of infection and the illness is associated with an increased incidence of childhood asthma. Data from both humans and animal models have linked severe disease in infants and the syndrome of vaccine-enhanced illness with an aberrant composition of CD4+ T cells, suggestive of an exaggerated Th2 response. Studies in murine models have shown that prior vaccination, coexisting allergic inflammation, or direct modulation of the cytokine milieu can profoundly influence the immune response to RSV and thereby affect the expression of disease. In addition, there are intrinsic antigenic properties of the RSV G glycoprotein that promote Th2 responses and eosinophilia. This paper proposes an integrated working model of how host and virus factors interact to determine the characteristics of RSV-induced illness. This model suggests strategies for the development of new vaccine and immunotherapeutic interventions, and creates a framework for asking additional questions about the immunopathogenesis of RSV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960663     DOI: 10.1016/s0162-3109(00)00233-2

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  44 in total

1.  Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

Authors:  Gertrud U Radu; Hayat Caidi; Congrong Miao; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

Authors:  John P DeVincenzo; Tom Wilkinson; Akshay Vaishnaw; Jeff Cehelsky; Rachel Meyers; Saraswathy Nochur; Lisa Harrison; Patricia Meeking; Alex Mann; Elizabeth Moane; John Oxford; Rajat Pareek; Ryves Moore; Ed Walsh; Robert Studholme; Preston Dorsett; Rene Alvarez; Robert Lambkin-Williams
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

4.  Gene expression differences in lungs of mice during secondary immune responses to respiratory syncytial virus infection.

Authors:  Annemieke Schuurhof; Louis Bont; Jeroen L A Pennings; Hennie M Hodemaekers; Piet W Wester; Annemarie Buisman; Lia C G H de Rond; Myra N Widjojoatmodjo; Willem Luytjes; Jan L L Kimpen; Riny Janssen
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 5.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

6.  The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity.

Authors:  John V Williams; Sharon J Tollefson; Joyce E Johnson; James E Crowe
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 7.  Human genetic factors and respiratory syncytial virus disease severity.

Authors:  Isao Miyairi; John P DeVincenzo
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

8.  Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein.

Authors:  Silvija I Staprans; Ashley P Barry; Guido Silvestri; Jeffrey T Safrit; Natalia Kozyr; Beth Sumpter; Hanh Nguyen; Harold McClure; David Montefiori; Jeffrey I Cohen; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

9.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

10.  Differential regulation of GM1 and asialo-GM1 expression by T cells and natural killer (NK) cells in respiratory syncytial virus infection.

Authors:  Martin L Moore; Michael H Chi; Kasia Goleniewska; Joan E Durbin; R Stokes Peebles
Journal:  Viral Immunol       Date:  2008-09       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.